We read with great interest the article published recently by Kartalis et al [1] . Our study group investigated the application of fl uorescence with the use of nanoparticles as a novel hybrid imaging method of pancreatic neuroendocrine tumors (pNETs). We demonstrated that a novel biomarker, namely calreticulin (CRT), is present in pNETs and may be targeted with fl uorescent gold quantum dots (AuQDs).
CRT is a ubiquitous Ca
2+
-binding protein with chaperone activity and a rather complex relation to various cancers: its overexpression is positively associated with various solid tumors, usually as an adverse prognostic indicator [2] ; however, contrary to its positive correlation to tumorigenesis and poor cancer prognosis, CRT also seems to promote immunogenic cancer cell death.
QDs are semiconductor nanocrystals with unique optical properties, such as highly tuneable fl uorescence and high photochemical stability; their relatively large surface-to-mass ratio enables them to perform as antibody or drug-carriers, attributes that provide QDs with an almost unlimited potential in cancer theranostics [3] . Our group have synthesized AuQDs with functionalized groups and bio-conjugated to anticalreticulin polyclonal antibodies (AuQD-antiCRT). Th ese AuQDs were manufactured to emit at 800 nm on excitation in the near infrared (NIR). It can be shown that conjugated AuQDs can be targeted specifi cally to in vitro pancreatic adenocarcinoma cell lines and ex vivo human pancreatic lesions. With Human Research Authority approval (REC Reference: 04/q0504/1) and appropriate patient consenting, paired tissue samples from resected pancreatic specimens post-pancreatectomy were obtained and stored in liquid nitrogen. Sections were then cut on a cryostat-microtome at approximately -25°C and mounted on Vectabond coated slides for observation under laser scanning confocal fl uorescence microscopy (LSCM, Nikon Eclipse TE 300). Once the fi xed tissues were characterized under the LSCM, selected paired slides were incubated with AuQD-antiCRT and observed under the LSCM. Th e resected pancreatic specimens were further processed and evaluated by a senior histopathologist.
Among the subjects was a 61-year-old female who underwent a Whipple's procedure for what proved to be a completely resected, well diff erentiated neuroendocrine neoplasm, TNM stage pT3N1pMx. Th e photomicrographs of the pathological tissues under laser excitation before and aft er incubation to AuQD-antiCRT are depicted in Fig. 1 . Illustrations (A) and (B) were captured by LSCM aft er 543 nm green laser beam excitation via a 650 nanometres/Long Pass (nm/LP) fl uorescence barrier, while (C) and (D) aft er 488 nm blue and 650 nm/LP fi ltering. Th ere was minimal signal emission aft er 543 nm excitation due to lower energy confi rming NIR emission (A). Post-incubation with AuQDantiCRT (B), there was NIR emission (pseudocolor) in 650/LP fi lter cut-off and therefore CRT expression. Images (C) and (D) also demonstrate NIR fl uorescence aft er AuQD-antiCRT incubation, more intense upon He-Ne (488 nm). Th ese two latter photographs also demonstrate some of the architectural appearances typical of pNETs, such as the cell nests (single arrows), trabeculi (double arrows) and gyriform patterns (arrowheads).
To the authors' best knowledge, this is the fi rst pictorial demonstration of CRT surface expression on pancreatic neuroendocrine malignancy with the use of fl uorescent quantum nanotechnology and tracing of pNETs with bio-stable, nondegradable fl uorophores, such as the AuQDs. Th ese fi ndings may facilitate further in vivo investigation on CRT expression on pNETs and on the application of QD-based theranostics on the detection and treatment of these conditions [4] . Finally, these fi ndings should trigger the design of in vivo animal studies on the fl uorescence-guided laparoscopic surgery (FGLS) aft er QDlabeling of CRT-rich solid pancreatic lesions [5] . Th e advantages of FGLS have already been described by Metildi et al [6] ; the theranostic advantage of QD-fl uorophores as both diagnostic and therapeutic tracers and carriers of immunochemical tumoricidal agents and their safety for in vivo applications in the treatment of pNETs are yet to be developed and proven. 
